Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example

Published:2010-01-29 Issue:4 Volume:66 Page:369-374
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Li-Wan-Po Alain,Farndon Peter,Craddock Charles,Griffiths Michael

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-009-0779-4.pdf

Reference44 articles.

1. Schwartz R (2002) A molecular star in the wars against cancer. N Engl J Med 347(7):462–463

2. Demetri GDvMM, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. A molecular star in the wars against cancer. N Engl J Med 347:472–480

3. Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Buttner R et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 6(4):249–251

4. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S et al (2003) Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101(2):473–475

5. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M et al (2009) Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115(3):551–560

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19;European Journal of Pharmaceutical Sciences;2023-05

2. Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study;CPT: Pharmacometrics & Systems Pharmacology;2021-10-24

3. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?;Cancer Medicine;2018-01-07

4. Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance;The Journal of Clinical Pharmacology;2017-06-15

5. PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib;Oncogene;2015-10-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3